|
1
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adam V, Dooms C and Vansteenkiste J: Lung
cancer at the intensive care unit: The era of targeted therapy.
Lung Cancer. 89:218–221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fournier P and Schirrmacher V: Oncolytic
Newcastle disease virus as cutting edge between tumor and host.
Biology (Basel). 2:936–975. 2013.PubMed/NCBI
|
|
5
|
Lam HY, Yeap SK, Pirozyan MR, Omar AR,
Yusoff K, Abd-Aziz S and Alitheen NB: Corrigendum to ‘Safety and
clinical usage of Newcastle disease virus in cancer therapy’.
BioMed Res Int. 2017:45294372017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Batliwalla FM, Bateman BA, Serrano D,
Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK and
Armstrong CA: A 15-year follow-up of AJCC stage III malignant
melanoma patients treated postsurgically with Newcastle disease
virus (NDV) oncolysate and determination of alterations in the CD8
T cell repertoire. Mol Med. 4:783–794. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cassel WA and Murray DR: A ten-year
follow-up on stage II malignant melanoma patients treated
postsurgically with Newcastle disease virus oncolysate. Med Oncol
Tumor Pharmacother. 9:169–171. 1992.PubMed/NCBI
|
|
8
|
Schirrmacher V, van Gool S and Stuecker W:
Breaking therapy resistance: An update on oncolytic Newcastle
disease virus for improvements of cancer therapy. Biomedicines.
7:662019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cuadrado-Castano S, Sanchez-Aparicio MT,
García-Sastre A and Villar E: The therapeutic effect of death:
Newcastle disease virus and its antitumor potential. Virus Res.
209:56–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keshavarz M, Nejad ASM, Esghaei M,
Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H and Ghaemi A:
Oncolytic Newcastle disease virus reduces growth of cervical cancer
cell by inducing apoptosis. Saudi J Biol Sci. 27:47–52. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Q, Rangaswamy US, Wang W, Robbins SH,
Harper J, Jin H and Cheng X: Evaluation of Newcastle disease virus
mediated dendritic cell activation and cross-priming tumor-specific
immune responses ex vivo. Int J Cancer. 146:531–541. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jarahian M, Watzl C, Fournier P, Arnold A,
Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V and
Momburg F: Activation of natural killer cells by Newcastle disease
virus hemagglutinin-neuraminidase. J Virol. 83:8108–8121. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Washburn B, Weigand MA, Grosse-Wilde A,
Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V and Walczak
H: TNF-related apoptosis-inducing ligand mediates tumoricidal
activity of human monocytes stimulated by Newcastle disease virus.
J Immunol. 170:1814–1821. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koks CA, Garg AD, Ehrhardt M, Riva M,
Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N and
Van Gool SW: Newcastle disease virotherapy induces long-term
survival and tumor-specific immune memory in orthotopic glioma
through the induction of immunogenic cell death. Int J Cancer.
136:E313–E325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ors-Kumoglu G, Gulce-Iz S and Biray-Avci
C: Therapeutic microRNAs in human cancer. Cytotechnology.
71:411–425. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li P, Wang Q and Wang H: MicroRNA-204
inhibits the proliferation, migration and invasion of human lung
cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo.
Int J Mol Med. 43:1149–1156. 2019.PubMed/NCBI
|
|
17
|
Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan
H and Xu S: Decreased expression of miR-204 in plasma is associated
with a poor prognosis in patients with non-small cell lung cancer.
Int J Mol Med. 36:1720–1726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghrici M, El Zowalaty M, Omar AR and
Ideris A: Induction of apoptosis in MCF-7 cells by the
hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus
Malaysian strain AF2240. Oncol Rep. 30:1035–1044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li N, Guo X, Liu L, Wang L and Cheng R:
Molecular mechanism of miR-204 regulates proliferation, apoptosis
and autophagy of cervical cancer cells by targeting ATF2. Artif
Cells Nanomed Biotechnol. 47:2529–2535. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raihan J, Ahmad U, Yong YK, Eshak Z,
Othman F and Ideris A: Regression of solid breast tumours in mice
by Newcastle disease virus is associated with production of
apoptosis related-cytokines. BMC Cancer. 19:3152019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dimitrov KM, Afonso CL, Yu Q and Miller
PJ: Newcastle disease vaccines - A solved problem or a continuous
challenge? Vet Microbiol. 206:126–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yurchenko KS, Zhou P, Kovner AV, Zavjalov
EL, Shestopalova LV and Shestopalov AM: Oncolytic effect of
wild-type Newcastle disease virus isolates in cancer cell lines in
vitro and in vivo on xenograft model. PLoS One. 13:e01954252018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lazar I, Yaacov B, Shiloach T, Eliahoo E,
Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A and
Ben-Yehuda D: The oncolytic activity of Newcastle disease virus
NDV-HUJ on chemoresistant primary melanoma cells is dependent on
the proapoptotic activity of the inhibitor of apoptosis protein
Livin. J Virol. 84:639–646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Shammari AM, Salman MI, Saihood YD,
Yaseen NY, Raed K, Shaker HK, Ahmed A, Khalid A and Duiach A: In
vitro synergistic enhancement of Newcastle disease virus to
5-fluorouracil cytotoxicity against tumor cells. Biomedicines.
4:32016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalyanasundram J, Hamid A, Yusoff K and
Chia SL: Newcastle disease virus strain AF2240 as an oncolytic
virus: A review. Acta Trop. 183:126–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang CX, Ye LW, Liu Y, Xu XY, Li DR, Yang
YQ, Sun LL and Yuan J: Antineoplastic activity of Newcastle disease
virus strain D90 in oral squamous cell carcinoma. Tumour Biol.
36:7121–7131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang S, Gao L, Thakur A, Shi P, Liu F,
Feng J, Wang T, Liang Y, Liu JJ, Chen M, et al: miRNA-204
suppresses human non-small cell lung cancer by targeting ATF2.
Tumour Biol. 37:11177–11186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang D, Li M, Yu Y, Shi H and Chen R:
microRNA-34a aggravates coxsackievirus B3-induced apoptosis of
cardiomyocytes through the SIRT1-p53 pathway. J Med Virol.
91:1643–1651. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geekiyanage H and Galanis E: MiR-31 and
miR-128 regulates poliovirus receptor-related 4 mediated measles
virus infectivity in tumors. Mol Oncol. 10:1387–1403. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rovira-Rigau M, Raimondi G, Marín MA,
Gironella M, Alemany R and Fillat C: Bioselection reveals miR-99b
and miR-485 as enhancers of adenoviral oncolysis in pancreatic
cancer. Mol Ther. 27:230–243. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li T, Pan H and Li R: The dual regulatory
role of miR-204 in cancer. Tumour Biol. 37:11667–11677. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Santoni G, Morelli MB, Santoni M, Nabissi
M, Marinelli O and Amantini C: Targeting transient receptor
potential channels by MicroRNAs drives tumor development and
progression. Adv Exp Med Biol. 1131:605–623. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tajbakhsh A, Mokhtari-Zaer A, Rezaee M,
Afzaljavan F, Rivandi M, Hassanian SM, Ferns GA, Pasdar A and Avan
A: Therapeutic potentials of BDNF/TrkB in breast cancer; current
status and perspectives. J Cell Biochem. 118:2502–2515. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang X, Jia Y, Wang X, Wang C, Lv C, Li X,
Chu Z, Han Q, Xiao S, Zhang S, et al: MiR-375 has contrasting
effects on Newcastle disease virus growth depending on the target
gene. Int J Biol Sci. 15:44–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Trobaugh DW and Klimstra WB: MicroRNA
regulation of RNA virus replication and pathogenesis. Trends Mol
Med. 23:80–93. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bian J, Wang K, Kong X, Liu H, Chen F, Hu
M, Zhang X, Jiao X, Ge B, Wu Y, et al: Caspase- and
p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells
by Newcastle disease virus. Arch Virol. 156:1335–1344. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yan Y, Liang B, Zhang J, Liu Y and Bu X:
Apoptotic induction of lung adenocarcinoma A549 cells infected by
recombinant RVG Newcastle disease virus (rL-RVG) in vitro. Mol Med
Rep. 11:317–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lamkanfi M and Kanneganti TD: Caspase-7: A
protease involved in apoptosis and inflammation. Int J Biochem Cell
Biol. 42:21–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
